A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Tremor Associated With Parkinson's Disease
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2018
At a glance
- Drugs CX 8998 (Primary)
- Indications Parkinson's disease; Tremor
- Focus Therapeutic Use
- Sponsors Cavion
- 09 Oct 2018 Trial design presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders
- 18 Jul 2018 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.
- 18 Jul 2018 Planned primary completion date changed from 1 Jun 2019 to 1 Sep 2019.